Vaccination against nicotine: an emerging therapy for tobacco dependence

• WHO: WHO Tobacco Free Initiative: Building Blocks for Tobacco Control: A Handbook (Ed.), WHO, Geneva, Switzerland (2004):3-13.
   Google Scholar
• SURGEON G: The Health Consequences of Smoking: A Report of the Surgeon General. (Ed.), Department of Health and Human Services, Centers for Disease, Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. Washington, DC, USA (2004).
   Google Scholar
• GAJALAKSHMI V, PETO R, KANAKA TS, JHA P: Smoking and mortality from tuberculosis and other diseases in India: retrospective study of 43000 adult male deaths and 35000 controls. Lancet (2003) 362(9383):507-515.
   PubMed Web of Science ®Google Scholar
• RIGOTTI NA: Clinical practice. Treatment of tobacco use and dependence. N. Engl. J. Med. (2002) 346(7):506-512.
   PubMed Web of Science ®Google Scholar
• LE FOLL B, GOLDBERG SR: Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology (Berl.) (2005):1-15.
   Google Scholar
• HARVEY DM, YASAR S, HEISHMAN SJ et al.: Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology (Berl.) (2004) 175(2):134-142.
   PubMed Web of Science ®Google Scholar
• HUKKANEN J, JACOB P III, BENOWITZ NL: Metabolism and disposition kinetics of nicotine. Pharmacol. Rev. (2005) 57(1):79-115.
   PubMed Web of Science ®Google Scholar
• NESTLER EJ: Is there a common molecular pathway for addiction? Nat. Neurosci. (2005) 8(11):1445-1449.
   PubMed Web of Science ®Google Scholar
• FAGERSTROM K, BALFOUR DJ: Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opin. Investig. Drugs (2006) 15(2):107-116.
   PubMed Web of Science ®Google Scholar
• LAVIOLETTE SR, VAN DER KOOY D: The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat. Rev. Neurosci. (2004) 5(1):55-65.
   PubMed Web of Science ®Google Scholar
• PIASECKI TM: Relapse to smoking. Clin. Psychol. Rev. (2006) 26(2):196-215.
   PubMed Web of Science ®Google Scholar
• KALMAN D, MORISSETTE SB, GEORGE TP: Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am. J. Addict., Am. Acad. Psychiatr. Alcohol Addict. (2005) 14(2):106-123.
   PubMed Web of Science ®Google Scholar
• HUGHES JR, GUST SW, SKOOG K, KEENAN RM, FENWICK JW: Symptoms of tobacco withdrawal. A replication and extension. Arch. Gen. Psychiatry (1991) 48(1):52-59.
   PubMed Web of Science ®Google Scholar
• JORENBY DE, LEISCHOW SJ, NIDES MA et al.: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. (1999) 340(9):685-691.
   PubMed Web of Science ®Google Scholar
• SILAGY C, LANCASTER T, STEAD L, MANT D, FOWLER G: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. (2004) 3:CD000146.
   Google Scholar
• HUGHES J, STEAD L, LANCASTER T: Antidepressants for smoking cessation. Cochrane Database Syst. Rev. (2007) 1:CD000031.
   PubMed Web of Science ®Google Scholar
• COE JW, BROOKS PR, VETELINO MG et al.: Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. (2005) 48(10):3474-3477.
   PubMed Web of Science ®Google Scholar
• JORENBY DE, HAYS JT, RIGOTTI NA et al.: Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA (2006) 296(1):56-63.
   PubMed Web of Science ®Google Scholar
• GONZALES D, RENNARD SI, NIDES M et al.: Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA (2006) 296(1):47-55.
   PubMed Web of Science ®Google Scholar
• TONSTAD S, TONNESEN P, HAJEK P et al.: Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA (2006) 296(1):64-71.
   PubMed Web of Science ®Google Scholar
• COHEN C, BERGIS OE, GALLI F et al.: SSR591813, a novel selective and partial α4β2 nicotinic receptor agonist with potential as an aid to smoking cessation. J. Pharmacol. Exp. Ther. (2003) 306(1):407-420.
   PubMed Web of Science ®Google Scholar
• KOSOWSKI AR, CEBERS G, CEBERE A, SWANHAGEN AC, LILJEQUIST S: Nicotine-induced dopamine release in the nucleus accumbens is inhibited by the novel AMPA antagonist ZK200775 and the NMDA antagonist CGP39551. Psychopharmacology (Berl.) (2004) 175(1):114-123.
   PubMed Web of Science ®Google Scholar
• COHEN C, PERRAULT G, GRIEBEL G, SOUBRIE P: Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology (2005) 30(1):145-155.
   PubMed Web of Science ®Google Scholar
• LE FOLL B, GOLDBERG SR, SOKOLOFF P: Dopamine D3 receptor ligands for the treatment of tobacco dependence. Expert Opin. Investig. Drugs (2007) 16(1):45-57.
   PubMed Web of Science ®Google Scholar
• BONESE KF, WAINER BH, FITCH FW, ROTHBERG RM, SCHUSTER CR: Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature (1974) 252(5485):708-710.
   PubMed Web of Science ®Google Scholar
• KENFORD SL, FIORE MC, JORENBY DE et al.: Predicting smoking cessation. Who will quit with and without the nicotine patch. JAMA (1994) 271(8):589-594.
   PubMed Web of Science ®Google Scholar
• SHIFFMAN S, FERGUSON SG, GWALTNEY CJ: Immediate hedonic response to smoking lapses: relationship to smoking relapse, and effects of nicotine replacement therapy. Psychopharmacology (Berl.) 184(3-4):608-618.
   PubMed Web of Science ®Google Scholar
• ROSE JE: Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology (Berl.) (2006) 184(3-4):274-285.
   PubMed Web of Science ®Google Scholar
• WATKINS SS, KOOB GF, MARKOU A: Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob. Res. (2000) 2(1):19-37.
   PubMedGoogle Scholar
• HIEDA Y, KEYLER DE, VANDEVOORT JT et al.: Active immunization alters the plasma nicotine concentration in rats. J. Pharmacol. Exp. Ther. (1997) 283(3):1076-1081.
   PubMed Web of Science ®Google Scholar
• PENTEL PR, MALIN DH, ENNIFAR S et al.: A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol. Biochem. Behav. (2000) 65(1):191-198.
   PubMed Web of Science ®Google Scholar
• ISOMURA S, WIRSCHING P, JANDA KD: An immunotherapeutic program for the treatment of nicotine addiction: hapten design and synthesis. J. Org. Chem. (2001) 66(12):4115-4121.
   PubMed Web of Science ®Google Scholar
• LINDBLOM N, DE VILLIERS SH, KALAYANOV G et al.: Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration (2002) 69(3):254-260.
   PubMed Web of Science ®Google Scholar
• CERNY EH, LEVY R, MAUEL J et al.: Preclinical development of a vaccine ‘against smoking’. Onkologie (2002) 25(5):406-411.
   PubMed Web of Science ®Google Scholar
• SANDERSON SD, CHERUKU SR, PADMANILAYAM MP et al.: Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant. Int. Immunopharmacol. (2003) 3(1):137-146.
   PubMed Web of Science ®Google Scholar
• MEIJLER MM, MATSUSHITA M, ALTOBELL LJ III, WIRSCHING P, JANDA KD: A new strategy for improved nicotine vaccines using conformationally constrained haptens. J. Am. Chem. Soc. (2003) 125(24):7164-7165.
   PubMed Web of Science ®Google Scholar
• MAURER P, JENNINGS GT, WILLERS J et al.: A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur. J. Immunol. (2005) 35(7):2031-2040.
   PubMed Web of Science ®Google Scholar
• DE VILLIERS SH, LINDBLOM N, KALAYANOV G et al.: Active immunization against nicotine alters the distribution of nicotine but not the metabolism to cotinine in the rat. Naunyn Schmiedebergs Arch. Pharmacol. (2004) 370(4):299-304.
   PubMed Web of Science ®Google Scholar
• DE VILLIERS SH, LINDBLOM N, KALAYANOV G et al.: Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration (2002) 69(3):247-253.
   PubMed Web of Science ®Google Scholar
• LESAGE MG, KEYLER DE, HIEDA Y et al.: Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats. Psychopharmacology (Berl.) (2006) 184(3-4):409-416.
   PubMed Web of Science ®Google Scholar
• MALIN DH, LAKE JR, LIN A et al.: Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol. Biochem. Behav. (2001) 68(1):87-92.
   PubMed Web of Science ®Google Scholar
• HUGHES JR, KEELY JP, NIAURA RS et al.: Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob. Res. (2003) 5(1):13-25.
   PubMed Web of Science ®Google Scholar
• WEST R, HAJEK P, STEAD L, STAPLETON J: Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction (2005) 100(3):299-303.
   PubMed Web of Science ®Google Scholar
• JEGERLEHNER A, TISSOT A, LECHNER F et al.: A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine (2002) 20(25-26):3104-3112.
   PubMed Web of Science ®Google Scholar
• BACHMANN MF, ROHRER UH, KUNDIG TM et al.: The influence of antigen organization on B cell responsiveness. Science (1993) 262(5138):1448-1451.
   PubMed Web of Science ®Google Scholar
• KUNDIG TM, SENTI G, SCHNETZLER G et al.: Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J. Allergy Clin. Immunol. (2006) 117(6):1470-1476.
   PubMed Web of Science ®Google Scholar
• AMBUHL PM, TISSOT AC, FULURIJA A et al.: A vaccine for hypertension based on virus-like particles: preclinical efficacy and Phase I safety and immunogenicity. J. Hypertens. (2007) 25(1):63-72.
   PubMed Web of Science ®Google Scholar
• CORNUZ J, KLINGLER K, MUELLER P, JUNGI, F, CERNY T: A therapeutic vaccine for nicotine dependence: results of a Phase I and a randomized Phase II study. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23(16S):1008.
   Google Scholar
• HIEDA Y, KEYLER DE, VANDEVOORT JT et al.: Immunization of rats reduces nicotine distribution to brain. Psychopharmacology (Berl.) (1999) 143(2):150-157.
   PubMed Web of Science ®Google Scholar
• SATOSKAR SD, KEYLER DE, LESAGE MG et al.: Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats. Int. Immunopharmacol. (2003) 3(7):957-970.
   PubMed Web of Science ®Google Scholar
• KEYLER DE, SHOEMAN D, LESAGE MG, CALVIN AD, PENTEL PR: Maternal vaccination against nicotine reduces nicotine distribution to fetal brain in rats. J. Pharmacol. Exp. Ther. (2003) 305(2):587-592.
   PubMed Web of Science ®Google Scholar
• HATSUKAMI DK, RENNARD S, JORENBY D et al.: Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin. Pharmacol. Ther. (2005) 78(5):456-467.
   PubMed Web of Science ®Google Scholar
• LINDBLOM N, DE VILLIERS SH, SEMENOVA S et al.: Active immunisation against nicotine blocks the reward facilitating effects of nicotine and partially prevents nicotine withdrawal in the rat as measured by dopamine output in the nucleus accumbens, brain reward thresholds and somatic signs. Naunyn Schmiedebergs Arch. Pharmacol. (2005):1-13.
   Google Scholar
• MIRE-SLUIS AR, BARRETT YC, DEVANARAYAN V et al.: Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods (2004) 289(1-2):1-16.
   PubMed Web of Science ®Google Scholar
• HASMAN A, HOLM S: Nicotine conjugate vaccine: is there a right to a smoking future? J. Med. Ethics (2004) 30(4):344-345.
   PubMed Web of Science ®Google Scholar
• HALL WD: Will nicotine genetics and a nicotine vaccine prevent cigarette smoking and smoking-related diseases? PLoS Med. (2005) 2(9):E266.
   PubMed Web of Science ®Google Scholar

Websites

• http://clinicaltrials.gov/show/NCT00387946 Efficacy and safety of dianicline treatment as an aid to smoking cessation in cigarette smokers (AMERIDIAN) (2007).
   Google Scholar
• http://clinicaltrials.gov/show/NCT00356976 Efficacy and safety of dianicline versus placebo as an aid to smoking cessation (EURODIAN) (2007).
   Google Scholar
• http://clinicaltrials.gov/show/NCT00218465 Effectiveness of GW-468816, an NMDA glycine site antagonist, for prevention of relapse to smoking (2007).
   Google Scholar
• http://clinicaltrials.gov/show/NCT00432575 Efficacy and safety of surinabant treatment as an aid to smoking cessation (SURSMOKE) (2007).
   Google Scholar
• http://www.addexpharma.com/ media-center/news-releases/ 24-january-2007/#c135 Announcement of the start of the Phase II trial with dopamine D1 receptor antagonist.
   Google Scholar
• http://www.uknscc.org/2005_UKNSCC/speakers/campbell_bunce.html Safety, immunogenicity and some early signs of efficacy for the nicotine vaccine, TA-NIC (2005).
   Google Scholar
• http://www.xenova.co.uk/PressReleases/ pr_20050303_02.html Announcement of the results of the clinical study with TA-NIC (2005).
   Google Scholar
• http://www.celticpharma.com/news/pr/release_050806.pdf Announcement of approval for a Phase II study in the UK (2006).
   Google Scholar
• http://www.celticpharma.com/news/pr/celtic_ta_nic_approval.pdf Announcement of approval for a Phase II study in the US (2007).
   Google Scholar
• http://www.cytos.com/doc/ Cytos_Press_E_051117.pdf Announcement of results of a Phase II study (2005).
   Google Scholar
• http://www.cytos.com/doc/ Cytos_Press_E_060202.pdf Announcement of results of a clinical dose-optimization study (2006).
   Google Scholar
• http://www.nabi.com/ Press release 02 May 2007. Announcement of results of a Phase II study.
   Google Scholar
• http://www.nabi.com/images/060107_ Phacilitate%20Hatsukami%20Web_ Final.pdf Accessed 04 June 2007.
   Google Scholar
• http://www.novartis.com/newsroom/news/index.shtml/ Press release 25 April 2007. Announcement from Novartis that it obtained the worldwide exclusive rights for NicQb from Cytos Biotechnology.
   Google Scholar